Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.
Blood|October 26, 2016
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphomaZijun Y Xu-Monette, Ling Li, John C Byrd, et al.
Research Square|January 27, 2025
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphomaKen Young, Wen-Yu Shi, Zijun Xu-Monette, et al.
Blood|January 25, 2013
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Zijun Y Xu-Monette, Aarthi Balasubramanyam, et al.
Oncotarget|June 24, 2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?Chi Young Ok, Qing Ye, Ling Li, et al.
Blood|March 2, 2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Zijun Y Xu-Monette, Alexander Tzankov, et al.
Haematologica|April 21, 2018
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM studyAntonio Cuneo, George Follows, Gian Matteo Rigolin, et al.
Blood|September 8, 2012
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y Xu-Monette, Lin Wu, Carlo Visco, et al.
The Lancet. Haematology|September 20, 2025
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Valentina Tabanelli, Maria Vittoria Sacchi, et al.
Blood Cancer Journal|July 17, 2025
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphomaWenyu Shi, Zijun Y Xu-Monette, Youchao Jia, et al.
Pageof 19